165
Views
14
CrossRef citations to date
0
Altmetric
Review

Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy

, MD PhD & , MD FRCP
Pages 31-41 | Published online: 20 Dec 2007
 

Abstract

The management of systemic lupus erythematosus (SLE) has improved thanks to a better understanding of the immunopathogenesis of the disease and important advances in drug development. In contrast to the worrying paucity of new therapies for SLE at the end of the last century, several agents have emerged as useful treatments for this condition in the last decade. The efficacy of mycophenolate mofetil in the treatment of patients with lupus nephritis has been recently established in several clinical trials. There are increasing data from open-label studies to support the belief that B-cell depletion using the chimeric antibody rituximab is useful in the treatment of SLE. However, larger double-blind clinical trials to confirm this belief are awaited. Other specific targeted therapeutic agents that act by inducing B-cell depletion, inhibiting co-stimulatory molecules necessary for T-cell activation, tolerising B and T cells, blocking pro-inflammatory cytokines or complement and immunoablation are exciting advances in the race towards improving the outcome for patients with SLE.

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.